Lipocine (NASDAQ:LPCN) experimental oral treatment for postpartum depression passed its final independent safety review, clearing the path for a critical data readout later this spring.
Hyperfine (NASDAQ:HYPR), the medical technology firm behind the first portable, AI-powered brain imaging system, reported a dramatic surge in fourth-quarter revenue, signaling a potential turning point for its bedside MRI technology.
Moderna (NASDAQ:MRNA) projected 2025 sales at the upper end of its forecast as a smaller-than-expected decline in U.S. vaccination rates and aggressive cost-cutting help the biotech giant navigate the post-pandemic landscape.
KORU Medical Systems (NASDAQ:KRMD) reported preliminary 2025 revenue that exceeded the high end of its guidance on Monday, as the medical technology firm prepares to pivot from its core immunology business into the high-growth oncology market.
Cellares and Cabaletta Bio (NASDAQ:CABA) announced a landmark regulatory achievement Monday, with the FDA clearing an Investigational New Drug (IND) Amendment to manufacture the autoimmune-focused CAR T therapy, rese-cel, using Cellares’ fully automated platforms.
GeneDx Holdings Corp. (NASDAQ:WGS) issued a bullish outlook for 2026 on Monday, forecasting revenue to exceed the half-billion-dollar milestone as the company’s pivot to high-margin exome and genome sequencing gains unprecedented traction.
DexCom (NASDAQ:DXCM) projected its annual revenue will climb toward $5.25 billion in 2026, marking a pivotal year for the glucose-monitoring leader as it phases out older hardware in favor of its longest-lasting sensor technology to date.
AbbVie (NYSE:ABBV) secured exclusive global rights to a novel cancer-fighting antibody from RemeGen Co. on Monday, marking one of the year’s largest oncology licensing agreements as the pharmaceutical giant moves to integrate next-generation bispecifics with its expanding "ADC" platform.
Shake Shack (NYSE:SHAK) signaled a period of aggressive expansion and improving profitability, issuing an upbeat 2026 outlook that highlights its evolution from a cult favorite to a dominant global restaurant platform.
GTCR announced the completion of its $24.25 billion sale of Worldpay to Global Payments (NYSE:GPN) on Monday, marking the conclusion of a complex three-way transaction that reshapes the landscape of the global payments industry.
SOPHiA GENETICS (NASDAQ:SOPH) reported a record-breaking performance for 2025, driven by a surge in demand for its AI-powered genomic analysis, as the company prepares for a major leadership transition and moves closer to profitability.
Viking Therapeutics (NASDAQ:VKTX) shares were in focus Monday after the company announced the peer-reviewed publication of its Phase 2 VENTURE study results, reinforcing the weight-loss potential of its lead candidate as it enters a pivotal year of Phase 3 testing.
